Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease

por Levy, Ofer, Apel, Arie, Alhdor, Hossam, Mizrachi, Avraham, Agmon-Levin, Nancy, Koren-Michowitz, Maya, Amit-Vazina, Mirit
Publicado 2022

Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study

por Gutwein, Odit, Herzog Tzarfati, Katrin, Apel, Arie, Rahimi‐Levene, Naomi, Ilana, Levy, Tadmor, Tamar, Koren‐Michowitz, Maya
Publicado 2023

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study

por Ram, Ron, Hagin, David, Kikozashvilli, Nino, Freund, Tal, Amit, Odelia, Bar-On, Yael, Beyar-Katz, Ofrat, Shefer, Gabi, Moshiashvili, Miguel Morales, Karni, Chen, Gold, Ronit, Kay, Sigi, Glait-Santar, Chen, Eshel, Rinat, Perry, Chava, Avivi, Irit, Apel, Arie, Benyamini, Noam, Shasha, David, Ben-Ami, Ronen
Publicado 2021